Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
Healthcare
$1.71 -0.90%
-$0.01 today
- Market cap
- $118.15M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
52W Low $1.03High $2.98
Volume 9.92M
Average 2.73M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$88.63M
FY 2025 · Annual
Investing Cash Flow
$14.04M
FY 2025 · Annual
-86.5% YoYFinancing Cash Flow
$53.05M
FY 2025 · Annual
+3.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| Deferred Income Tax | 0 | 4.03M | (32.05K) | 0 | 0 |
| Stock-Based Compensation | 26.34M | 22.56M | 11.07M | 6.6M | 3.76M |
| Change in Working Capital | 50.35M | 19.83M | (10.26M) | (2.66M) | (9.22M) |
| Accounts Receivables | 11.03M | (3.71M) | 9.33M | 1.21M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 26.14M | 32.61M | (45.99M) | (3.37M) | (6.42M) |
| Other Working Capital | 13.18M | (9.07M) | 26.4M | (504.04K) | (2.8M) |
| Other Non-Cash Items | 6.53M | 11.69M | 6.47M | (3.88M) | (1.21M) |
| Operating Cash Flow | (215.71M) | (216.22M) | (124.37M) | (104.08M) | (88.63M) |
| Capital Expenditures | (1.23M) | (969.15K) | (320.9K) | (487.83K) | (285.7K) |
| Acquisitions (Net) | 0 | (2M) | 6.22M | 0 | 0 |
| Purchases of Investments | (348.95M) | (248.53M) | (203.48M) | (54.14M) | (4.95M) |
| Sales of Investments | 174.84M | 361.08M | 284.93M | 158.64M | 19.27M |
| Other Investing Activities | 0 | 0 | 0 | 59.32K | 0 |
| Investing Cash Flow | (175.34M) | 109.59M | 87.36M | 104.07M | 14.04M |
| Debt Repayment | 0 | 0 | 0 | (16.42M) | 0 |
| Common Stock Issued | 209.44M | 82.96M | 5.46M | 68.31M | 53.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.06M | (1.11M) | (466.65K) | (420.8K) | (110.78K) |
| Financing Cash Flow | 211.5M | 81.84M | 5M | 51.48M | 53.05M |
| Effect of Forex Changes | (30.13K) | (25.56K) | (3.92K) | 32.4K | 0 |
| Net Change in Cash | (179.58M) | (24.81M) | (32.02M) | 51.5M | (21.54M) |
| Free Cash Flow | (216.94M) | (217.18M) | (124.69M) | (104.56M) | (88.92M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$84.9M
+ D&A$3.0M
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
- Working Capital-$9.2M
- Other Non-Cash-$1.2M
= Operating Cash Flow-$88.6M
- Capex-$285.7K
= Free Cash Flow-$88.9M
Analysis
FY2025 free cash flow is -$88.9M. FCF conversion is 104.7% of net income. Operating cash flow was -$88.6M, with capex of -$285.7K. The largest bridge item is Working Capital at -$9.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| FWP | FWP filing | Nov 6, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 424B5 | 424B5 filing | Nov 5, 2026 |
Does INO generate free cash flow?
Inovio Pharmaceuticals, Inc. (INO) generated -$88.92M of free cash flow in fiscal 2025.
How much operating cash flow does INO produce?
Operating cash flow was -$88.63M, before capital expenditures of $285,698.00.
Continue the stock analysis
Jump to another research area for this company.